223 related articles for article (PubMed ID: 38372871)
41. Individualizing osteoporosis therapy.
Silverman S; Christiansen C
Osteoporos Int; 2012 Mar; 23(3):797-809. PubMed ID: 22218417
[TBL] [Abstract][Full Text] [Related]
42. Medical treatment of vertebral osteoporosis.
Lippuner K
Eur Spine J; 2003 Oct; 12 Suppl 2(Suppl 2):S132-41. PubMed ID: 13680313
[TBL] [Abstract][Full Text] [Related]
43. [Oral osteoporosis: a review and its dental implications].
Inagaki K; Kurosu Y; Sakano M; Yamamoto G; Kikuchi T; Noguchi T; Yano H; Izawa H; Hachiya Y
Clin Calcium; 2007 Feb; 17(2):157-63. PubMed ID: 17272871
[TBL] [Abstract][Full Text] [Related]
44. Recent advance of small-molecule drugs for clinical treatment of osteoporosis: A review.
Zhang JY; Zhong YH; Chen LM; Zhuo XL; Zhao LJ; Wang YT
Eur J Med Chem; 2023 Nov; 259():115654. PubMed ID: 37467618
[TBL] [Abstract][Full Text] [Related]
45. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E
Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666
[TBL] [Abstract][Full Text] [Related]
46. [[Antiresorptive agents in the treatment of osteoporosis].
Novak S
Reumatizam; 2014; 61(2):89-94. PubMed ID: 25427401
[TBL] [Abstract][Full Text] [Related]
47. [Selective estrogen receptor modulators in treatment of postmenopausal osteoporosis].
Meczekalski B; Czyzyk A
Ginekol Pol; 2009 Mar; 80(3):213-7. PubMed ID: 19382614
[TBL] [Abstract][Full Text] [Related]
48. Safety concerns with the long-term management of osteoporosis.
Reginster JY; Pelousse F; Bruyère O
Expert Opin Drug Saf; 2013 Jul; 12(4):507-22. PubMed ID: 23614635
[TBL] [Abstract][Full Text] [Related]
49. Use of FRAX®-based fracture risk assessments to identify patients who will benefit from osteoporosis therapy.
Silverman SL; Komm BS; Mirkin S
Maturitas; 2014 Nov; 79(3):241-7. PubMed ID: 25124532
[TBL] [Abstract][Full Text] [Related]
50. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.
Hiligsmann M; Reginster JY
Pharmacoeconomics; 2011 Oct; 29(10):895-911. PubMed ID: 21692551
[TBL] [Abstract][Full Text] [Related]
51. Perioperative Medical Management of Spine Surgery Patients With Osteoporosis.
Lubelski D; Choma TJ; Steinmetz MP; Harrop JS; Mroz TE
Neurosurgery; 2015 Oct; 77 Suppl 4():S92-7. PubMed ID: 26378362
[TBL] [Abstract][Full Text] [Related]
52. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
Levis S; Theodore G
J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
[TBL] [Abstract][Full Text] [Related]
53. Are estrogen-related drugs new alternatives for the management of osteoarthritis?
Xiao YP; Tian FM; Dai MW; Wang WY; Shao LT; Zhang L
Arthritis Res Ther; 2016 Jun; 18():151. PubMed ID: 27352621
[TBL] [Abstract][Full Text] [Related]
54. The comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: A retrospective case-control study.
Kim SK; Kim JW; Lee H; Park SH; Choe JY; Kim B
Medicine (Baltimore); 2023 Jun; 102(26):e34219. PubMed ID: 37390268
[TBL] [Abstract][Full Text] [Related]
55. What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?
Miller PD; Derman RJ
Osteoporos Int; 2010 Nov; 21(11):1793-802. PubMed ID: 20309524
[TBL] [Abstract][Full Text] [Related]
56. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
57. [Bone remodeling: new therapeutic approaches].
Ferrari S
Rev Med Suisse; 2009 Jun; 5(207):1325-8. PubMed ID: 19626933
[TBL] [Abstract][Full Text] [Related]
58. Vitamin D status and parathyroid hormone concentrations influence the skeletal response to zoledronate and denosumab.
Mosali P; Bernard L; Wajed J; Mohamed Z; Ewang M; Moore A; Fogelman I; Hampson G
Calcif Tissue Int; 2014 May; 94(5):553-9. PubMed ID: 24509506
[TBL] [Abstract][Full Text] [Related]
59. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.
Miller PD; Pannacciulli N; Brown JP; Czerwinski E; Nedergaard BS; Bolognese MA; Malouf J; Bone HG; Reginster JY; Singer A; Wang C; Wagman RB; Cummings SR
J Clin Endocrinol Metab; 2016 Aug; 101(8):3163-70. PubMed ID: 27270237
[TBL] [Abstract][Full Text] [Related]
60. Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy.
Leder BZ
Curr Osteoporos Rep; 2017 Apr; 15(2):110-119. PubMed ID: 28303448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
